Department Of Pediatric Oncology
Alice Lee, MD

Alice Lee, MD specializes in the care of children and adolescents with solid tumors, especially neuroblastoma, Wilms' tumor, and sarcomas. She also conducts research to develop and evaluate new anticancer therapies for young patients.

Dr. Lee takes a personal interest in her patients. She says, "The patients I care for are amazing. Regardless of how a child is doing during treatment, they just want to be kids. I form bonds with their families that are rich and lifelong. They come to us each day hoping their children get better, while we come to work each day hoping to advance the field with more effective therapies so more children get better. My goal is to know I've done all we can for every one of our patients, and to further therapy by developing new anticancer drugs that become a standard part of care for pediatric cancers in the future."

Dr. Lee is also intrigued by the science of pediatric oncology. In this ever-changing field, much remains to be learned, which offers her an intellectual challenge. As the institution's principal investigator for the Children's Oncology Group (COG; the nation's leading pediatric cancer research consortium), Dr. Lee and her team are evaluating new therapies and new combinations of existing therapies to identify more effective, less toxic treatments for children with cancer.

Dr. Lee is proud to be part of the team at NewYork-Presbyterian/Morgan Stanley Children's Hospital at Columbia University Medical Center, where patients have all the specialists they may need in one location, including pediatric critical care onsite if serious complications arise. Her division has leaders in every type of pediatric cancer or blood disorder.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A study for children and adolescents with relapsed or refractory acute myeloid leukemia using study drug Lenalidomide
Cancer [ CLOSED ] A study for children with high-risk neuroblastoma using study drug unituxin
Pediatric Solid Tumors [ CLOSED ] A study for children with refractory solid tumors, including CNS tumors using study drug ramucirumab
Leukemia [ CLOSED ] A study of adding study drug Sorafenib to the usual treatment in children and teens with AML (Acute Myeloid Leukemia)
Hearing Loss [ CLOSED ] A study to Assess Safety and Effectiveness of Study Drug OTO-104 in Patients at Risk of Hearing Loss From Cisplatin Chemotherapy
Pediatrics [ CLOSED ] A study for children, adolescents and young adults with high-risk acute lymphoblastic Leukemia (HR B-ALL) using study drug Ruxolitinib
Pediatric Solid Tumors [ CLOSED ] Study of Entinostat in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma
Cancer [ CLOSED ] Study of Drug in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
Pediatric Solid Tumors [ CLOSED ] Study of Experimental Drug in Pediatric Patients with Solid Tumors, including CNS Tumors
Pediatric Solid Tumors [ CLOSED ] Study of MK-1775 in Combination with Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumor
Cancer [ CLOSED ] Palbociclib and Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)